Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3

Xiangrong Cui, Jianping Liu, Lu Bai, Jie Tian and Jing Zhu

Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China

Mesenchymal stem cells (MSCs) have the potential to be the source for cell-based therapies. However, MSCs can undergo malignant transformation in a tumor microenvironment where a high level of interleukin (IL)-6 is present. In this study, we investigated the role of IL-6 and signal transducer and activator of transcription 3 (STAT3) signaling in malignant transformation of MSCs. Rat MSCs were isolated and indirectly cocultured with C6 glioma cells. Coculture of MSCs with astrocytes was used as a control. After 7 days of culture, the cells were assessed for malignant transformation using MTT assay and immunofluorescence staining. The levels of hepatocyte growth factor, IL-6, and basic fibroblast growth factor, and the expression of STAT3 and soluble IL-6 receptor in the cultured cells and conditioned media were measured using RT-PCR, ELISA, and Western blot analysis. The expression levels of STAT3 downstream targets, CyclinD1 and Bcl-xl, were determined as well. Our data showed that almost all of the MSCs became phenotypically malignant after indirect coculture with glioma cells, which was confirmed by tumor formation assays when these cells were injected into nude mice. The expression of IL-6 was significantly increased in MSCs cocultured with glioma cells, which was associated with significantly increased expressions of soluble IL-6 receptor, transmembrane glycoprotein GP130, STAT3, phosphorylated STAT3, CyclinD1, and Bcl-xl. Similar results were obtained when the MSCs were treated with IL-6. Treatment of the cocultured MSCs and glioma cells with STA-21, to block the constitutive STAT3 signaling, reduced the risk of MSC tumor-like transformation in the tumor microenvironment. These data suggest that IL-6 plays a critical role in malignant transformation of rat MSCs, which is associated with an enhancement of the STAT3 signaling pathway in the tumor microenvironment.
Fig. 1. Identification of astrocytes and mesenchymal stem cells (MSCs). (a) Using immunofluorescence staining, the cytoplasm of astrocytes and C6 glioma cells were stained positive for glial fibrillary acidic protein (GFAP). (b) Immunofluorescence staining showed that MSCs were stained positive for CD71 and CD105.

Fig. 2. Characteristics of mesenchymal stem cells (MSCs) after coculture with C6 glioma cells. (a) Microscopic examination revealed that the cells showed tumor cell-like morphology a few days after indirect coculture with C6 glioma cells. (b) MTT assay showed the cells after indirect coculture with C6 glioma cells had a growth curve identical to that of cultured glioma cells with a much faster cell proliferation rate than that of control cells. *P < 0.05 compared to control cells.

Fig. 3. Tumor growth in nude mouse after injection of mesenchymal stem cells (MSCs) cocultured with C6 glioma cells. (a) H&E staining of tissue at cell injection sites in nude mice showed clusters of tumor cells after injection of glioma cells or MSCs cocultured with C6 glioma cells. Only skeletal muscle cells were visualized at the sites injected with the normal control cells. (b) Tumor growth curve in nude mice after injection of MSCs into the mouse nail pads. The xenograft volume was measured every 5 days up to 30 days following cell inoculation.

*p < 0.05 compared to control cells.

© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
The experiment was divided into four groups: (i) experimental group (MSCs and C6 glioma indirect coculture); (ii) positive control (cultured C6 glioma cells); (iii) negative control group (MSCs and C6 glioma indirect coculture); (iv) cultured control (cultured C6 glioma cells); (v) excessive IL-6; and the control group (MSCs cultured without IL-6).

**Inhibition of STAT3 by STA-21.** To examine the effect of inhibition of STAT3, MSCs cocultured with C6 glioma cells were treated with different doses (0–50 μM) of STAT3-specific inhibitor STA-21 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 24 h. The compound of STA-21 was solubilized in DMSO (100 mmol/L), which was further diluted in injectable saline for animal studies.

**Enzyme-linked immunosorbent assay for HGF, IL-6, bFGF, and sIL-6R.** The conditioned media of the cells in each group were analyzed for HGF, IL-6, bFGF, and sIL-6R levels using an ELISA kit (Westang, Shanghai, China) according to the manufacturer's instructions. Sandwich ELISA protocols were used, and calibration was done with standard HGF, IL-6, bFGF, and sIL-6R provided in the kit.

**Quantitative real-time PCR analysis.** Quantitative real-time PCR assay was used to assess the transcriptional expression of tumor-related genes including p53, MDM2, STAT3, CyclinD1, and Bcl-xl. Total RNAs were extracted from cells, and reverse-transcribed with a kit from TaKaRa (Otsu, Japan) for the assay using a SYBR Green dye kit (TaKaRa) as described previously. β-actin was used as the endogenous housekeeping gene to normalize the mRNA levels. The specific primers were: p53, 5′-gcctacaacagctcaacac-3′ (forward) and 5′-ctgcctaatgacctaatc-3′ (reverse); MDM2, 5′-ctataaggtggtattcataacg-3′ (forward) and 5′-gttttcttcagctctc-3′ (reverse); STAT3, 5′-gcctaatctggtgat-ac-3′ (forward) and 5′-tctttggtgggacagaac-3′ (reverse); CyclinD1, 5′-gcctaatcact-gacact-ac-3′ (forward) and 5′-tggcttcaggctct-3′ (reverse); and Bcl-xl, 5′-cagccagttggaggttacagacggtggag-3′ (forward) and 5′-ggtttagagcactaagct-3′ (reverse). The results were expressed as the mean of 2-ΔΔCT (calculated according to the manufacturer's instructions) ± SD.

**Immunofluorescent staining.** All the cell preparations were incubated with the primary antibodies against p53 (mouse monoclonal, 1:80; Santa Cruz Biotechnology), MDM2 (mouse monoclonal, 1:80; Santa Cruz Biotechnology), STAT3 (mouse monoclonal, 1:20; Abcam), and p-STAT3 (mouse monoclonal, 1:100; Cell Signaling Technology, Danvers, MA, USA), and the astrocytes were incubated with the primary antibody against GFAP (mouse monoclonal, 1:100; Thermo Fisher Scientific, Waltham, MA, USA) overnight, followed by exposure to the corresponding tetramethylrhodamine isothiocyanate-conjugated secondary antibodies (1:100 goat anti-mouse and goat anti-rabbit; Santa Cruz Biotechnology) at 37°C for 1 h. The cells were subsequently examined using a BX51 fluorescence microscope (Olympus, Tokyo, Japan).

**Western blot analysis.** Cell lysates were prepared from each group for Western blot analysis to determine the expression level of tumor-related proteins P53, MDM2, STAT3, p-STAT3, GP130, CyclinD1, and Bcl-xl. After preparation, the samples were incubated with mouse anti-P53, MDM2 mAb (1:200; Santa Cruz Biotechnology), STAT3 mAb (1:20; Abcam), p-STAT3 mouse mAb (1:100; Cell Signaling Technology), CyclinD1 and Bcl-xl antibodies (1:1000; Epitomics, Burlingame, CA, USA), mouse anti-rabbit β-actin mAb (1:5000; Boster Bio-engineering, Wuhan, China) as recommended by the manufacturers. The preparations were then exposed to goat anti-mouse or rabbit antibody (1:2000; Zhongshan Bio-engineering, Beijing, China) in PBS.

**Cell counting after IL-6 treatment.** The MSCs were divided into two groups: the experimental group (MSCs cultured with excessive IL-6); and the control group (MSCs cultured without IL-6). Cell growth curves were obtained for each group after 1 and 2 months of culture to determine the effect of IL-6 on promoting the proliferation of MSCs and malignant transformation.

**Cell viability assay.** Cell viability was assayed by measuring blue formazan that was generated from MTT by mitochondrial dehydrogenase, which is active only in live cells. Cells in each group were seeded in 96-well flat-bottomed microtiter plates (3000–5000 cells/well), and were incubated for 1–7 days at 37°C with 5% CO2 and 95% O2. Then MTT was added to each well and incubated for 4 h at 37°C. The formazan product was dissolved by adding 200 μL DMSO to each well, and absorbance was read at 490 nm. All measurements were
carried out in triplicate, and each experiment was repeated at least three times.

**In vivo tumorigenesis.** Six-week-old SPF grade male BALB/c nude mice were purchased from the Experimental Animal Center at Chongqing Medical University. These mice were fed a standard rodent diet and water ad libitum in an aseptic laminar flow room with 60–70% humidity at 25°C. A total of 50 µL cell preparations in each group (containing $2 \times 10^6$ tumor cells) was injected into the nail pad of the mice s.c. The tumors were harvested 4–8 weeks after transplantation, and examined morphologically and cytohistologically using standard H&E staining.

**Statistical analysis.** All data were expressed as the mean ± SD, and statistically analyzed using one-way ANOVA. The
differences were considered statistically significant when $P < 0.05$.

**Results**

**Identification of astrocytes and MSCs.** To ensure that the cells used in the present study were astrocytes and MSCs, the phenotype of the cells was determined by measuring the specific cell markers for rat astrocyte GFAP and MSC CD71 and CD105, respectively. As shown in Figure 1(a), more than 95% of the astrocytes and C6 glioma cells under immunofluorescence staining were positive for GFAP, but the ratio of the expression of MSCs was only 13%, confirming that these cells were astrocytes. As expected, more than 95% of the cells stained double-positive for CD71 and CD105, confirming that these cells were MSCs (Fig. 1b,c).

**Transformation of MSCs to tumor cells in simulated tumor microenvironment.** As shown in Figure 2(a), the morphology of the cells cocultured with C6 glioma cells was significantly changed. The cytoplasm contracted toward the perinuclear area, and the cells became longer and thinner with smaller nuclei compared to normal MSCs, which were similar to the glioma cells. The cells in this group also grew much faster than the normal MSCs. The growth curve of the MSCs cocultured with C6 glioma cells was similar to that of glioma cells, as shown in Figure 2(b) ($P < 0.05$).
suggesting malignant transformation of MSCs after coculture with C6 glioma cells.

In vivo tumor formation by MSCs cocultured with C6 glioma cells. In order to determine the tumorigenicity of the cells after malignant transformation, the MSCs cocultured with C6 glioma cells or with normal cells were injected into nude mice. Thirty days after the injection, the injected MSCs cocultured with C6 glioma cells or glioma cells alone developed into an invasive tumor that was composed of undifferentiated cells and infiltrated to the peripheral musculus, as examined by H&E staining (Fig. 3a). After the injection, the volume of invasive tumors in nude mice for each group was measured every day by rule, as shown in Figure 3(b). Tumor growth and progression were similar for cells cocultured with C6 glioma cells, and glioma cells alone. The invasive tumors in the two groups grew much faster than in the normal group, further suggesting the malignant nature of the cells after coculture with C6 glioma cells. No tumor growth was observed after injection of normal MSCs or MSCs cocultured with normal astrocytes.

Expression of HGF and IL-6, not bFGF, was increased in MSCs cocultured with C6 glioma cells. As shown in Figure 4, the levels of HGF and IL-6 were significantly increased in the conditioned media of the MSCs cocultured with C6 glioma cells compared to that of normal MSCs or the MSCs cocultured with normal astrocytes \( (P < 0.01) \). However, no significant change in the expression of bFGF was observed in the cells cocultured with C6 glioma cells \( (P > 0.05) \). There was no significant difference in the expression of HGF, IL-6, or bFGF between normal MSCs and the cells cocultured with astrocytes. Analysis with ELISA showed that the level of sIL-6R in the conditioned media of glioma cells and the cells cocultured with C6 glioma cells was also significantly increased \( (P < 0.05) \) along with an increased expression of the membrane protein GP130 (as determined by immunofluorescence staining in these cells compared with normal MSCs \( (P < 0.05) \).

Expression of STAT3, p-STAT3, CyclinD1, and Bcl-xl increased in MSCs cocultured with C6 glioma cells. Analyses using quantitative RT-PCR (Fig. 5c) and Western immunoblotting (Fig. 5d) showed that expression of STAT3, p-STAT3, CyclinD1, and Bcl-xl in STA-21-treated groups were significantly increased compared to the group without STA-21 treatment.

Interleukin-6 promoted proliferation of MSCs and expression of P53, MDM2, and STAT3 in MSCs. As shown in Figure 6(a), normal MSCs displayed the characteristic morphology of enlarged and fibroblast-like cells in a well-organized orientation, whereas the MSCs became smaller and longer with reduced cytoplasm around the nucleus after 2 months of culture with an excessive amount of IL-6 (200 pg/mL). The cells also grew much faster after 2 months of treatment with...
IL-6, as shown in Figure 6(b). The expression of P53, MDM2, and STAT3 (both mRNAs and proteins) was significantly increased in the cells after 2 months of treatment with IL-6 over control (Fig. 6c–e) (P < 0.05). The mutant P53 protein was found in 25.2% of cells treated with IL-6, whereas no mutant P53 was present in the control MSCs (P < 0.05). Expression of MDM2 protein was increased significantly, with 32.33% and 87.26% of cells positive for MDM2 in the control and IL-6-treated cells, respectively (P < 0.05).

**Interleukin-6-treated MSCs produced tumor in nude mice.** When IL-6-treated cells were injected into the skin of nude mice, visible tumor growth was observed in the injection site 3 months after injection (Fig. 7a), whereas no tumor growth was present at the site injected with control cells (Fig. 7c). Staining with H&E revealed different sized clusters of amorphous tumor cells without specific cell orientation in the injection site with the IL-6-treated cells (Fig. 7b). Necrotic cells were visible in the center of some cell clusters. Only normal skeletal muscle structure was seen on H&E staining in the inoculation site with control cells (Fig. 7d).

**Effect of inhibition of STAT3.** As shown in Figure 8(a), MSCs cocultured with C6 glioma cells were treated with 0–50 μM STA-21 for 24 h and the cell proliferation inhibition rate was analyzed using MTT. Significant cell growth inhibition was observed in STA-21 treatment groups compared with the group without STA-21 treatment (P < 0.05). Analyses using Western immunoblotting (Fig. 8b) indicated that the expression of STAT3, p-STAT3, CyclinD1, and Bcl-xl was significantly decreased in STA-21 treatment groups compared to the group without STA-21 treatment (P < 0.05).

**Discussion**

Recently, we showed for the first time that, after indirect coculture with glioma C6 cells, MSCs showed the characteristics of malignant cells, such as tumor cell-like morphology, cell proliferation, and cell cycle, development of poorly differentiated tumors, and in vivo invasive behavior.(17) The fact that rat MSCs underwent malignant transformation after a short period of indirect coculture with cancer cells clearly indicated that the tumor microenvironment could be an important determinant for the fate of MSCs.

It has been reported that high levels of HGF, IL-6, bFGF, and other JAK signaling molecules are present in the C6 glioma microenvironment.(8–10) In the present study, we observed that the expression of IL-6 is significantly increased in C6 glioma cells and cells cocultured with C6 glioma cells, whereas the others (HGF and bFGF) were not changed in the cells after coculture. Interleukin-6 is a multifunctional cytokine, and is an important factor in various diseases including rheumatoid arthritis, lymphoproliferative disorders, multiple myeloma, osteoporosis, and Alzheimer’s disease. (26) An elevated serum IL-6 level has been correlated with poor prognosis in patients with a variety of cancers.(27) Interleukin-6 binds to sIL-6R, and forms a circulating complex. (25) This soluble complex then binds to the cells that express GP130, and induces intracellular signal transduction and gene expression in the target cells.(26) In the present study, significantly high levels of IL-6, sIL-6R, and GP130 were detected in MSCs that were indirectly cocultured with cancer cells, indicating that the malignant transformation of MSCs is correlated with IL-6. Our data are consistent with reports from previous studies. (20–22)

It has been shown that increased IL-6 expression can result in an increase of the expression and nuclear translocation of STAT3.(22) Interleukin-6 and related STAT3 signaling pathways play a critical role in the survival of intestinal epithelial cells in colitis-associated cancer. Constitutive activation of STAT3 provides cancer cells with growth and survival advantages through activating multiple signaling pathways and regulations of a broad range of gene expressions in the cells.(15)

In the present study, the expression and activation of STAT3 (both in vivo and in vitro) and its downstream targets such as CyclinD1 and Bcl-xl were significantly increased in MSCs indirectly cocultured with cancer cells, compared to control cells. Similar results were obtained when MSCs were treated with a similar level of IL-6 as that in the tumor microenvironment. Additionally, through treating cocultured MSCs with glioma using STA-21, to block the constitutive STAT3 signaling, the risk of MSC tumor-like transformation in the tumor microenvironment was reduced. These data suggest that IL-6 and the related STAT3 signaling pathway might be critically involved in the malignant transformation of MSCs in a tumor microenvironment. The information is clinically important in patient selection for cell-based therapies using MSCs. Caution should be taken when MSCs are used in patients with an underlying malignancy.

**Acknowledgments**

This study was supported by the National Science Foundation of China (Grant No. 31140035), and the Foundation of Chongqing Science and Technology Commission (Grant Nos. CSTC, 2011jjA10060).

**Disclosure Statement**

The authors have no conflict of interest.
11 Sturzu A, Heckl S. Magnetic resonance imaging of human glioma cells by means of an interleukin-6 receptor-targeted contrast agent. *Chem Biol Drug Des* 2010; **75**: 369–74.

12 Knüpfer H, Preiss R. Lack of knowledge: breast cancer and the soluble interleukin-6 receptor. *Breast Care* 2010; **5**: 177–80.

13 He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. *Cell Res* 2011; 21(1): 159–68.

14 Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. *Mol Interv* 2011; **11**: 18–26.

15 Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. *Drug Resist Updat* 2010; **13**: 67–78.

16 Chedrawy EG, Wang JS, Nguyen DM, Shum-Tim D, Chiu RC. Incorporation and integration of implanted myogenic and stem cells into native myocardial fibers: anatomic basis for functional improvements. *J Thorac Cardiovasc Surg* 2002; **124**: 584–90.

17 Liu J, Zhang Y, Bai L, Cui X, Zhu J. Rat bone marrow mesenchymal stem cells undergo malignant transformation via indirect co-cultured with tumour cells. *Cell Biochem Funct* 2012; **30**: 650–6.

18 Schwartz JP, Wilson DJ. Preparation and characterization of type 1 astrocytes cultured from adult rat cortex, cerebellum, and striatum. *Glia* 1992; **5**: 75–80.

19 Arikawa E, Sun Y, Wang J *et al.* Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC)study. *BMC Genomics* 2008; **9**: 328.

20 Niu G, Wright KL, Ma Y *et al.* Role of Stat3 in regulating p53 expression and function. *Mol Cell Biol* 2005; **25**: 7432–40.

21 Masuda A, Kamai T, Abe H, Arai K, Yoshida K. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma? *Biomed Res* 2009; **30**: 171–6.

22 Liu Y, Lin J. Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy. *Future Oncol* 2011; **7**: 161–4.

23 Jndoyan Z, Martirosyan N. The role of aldosterone and IL-6 in the pathogenesis of inflammation in familial Mediterranean fever. *Georgian Med News* 2012; **206**: 44–8.

24 Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin 6 and its receptor, key players in hepatobiliary inflammation and cancer. *Transl Gastrointest Cancer* 2012; **1**: 58–70.

25 Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. *World J Clin Oncol* 2011; **2**: 384–96.

26 Hirano T. Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. *Proc Jpn Acad Ser B Phys Biol Sci* 2010; **86**: 717–30.

27 Wang Y, Li L, Guo X *et al.* Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. *Cytokine* 2012; **59**: 226–36.

28 Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. *J Cell Biol* 2008; **182**: 855–63.